SCM
Soleus Capital Management Portfolio holdings
AUM
$1.45B
This Quarter Return
+11.17%
1 Year Return
+18.23%
3 Year Return
+274.85%
5 Year Return
+440.77%
10 Year Return
–
AUM
$900M
AUM Growth
+$900M
(+11%)
Cap. Flow
-$78M
Cap. Flow
% of AUM
-8.67%
Top 10 Holdings %
Top 10 Hldgs %
42.92%
Holding
115
New
38
Increased
26
Reduced
29
Closed
13
Top Buys
| 1 |
Teva Pharmaceuticals
TEVA
|
$32M |
| 2 |
United Therapeutics
UTHR
|
$23.5M |
| 3 |
Humana
HUM
|
$17.4M |
| 4 |
Surmodics
SRDX
|
$13.9M |
| 5 |
The Beauty Health Co
SKIN
|
$11.6M |
Top Sells
| 1 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
$51.8M |
| 2 |
Exact Sciences
EXAS
|
$36.3M |
| 3 |
Smith & Nephew
SNN
|
$15.5M |
| 4 |
SI-BONE Inc
SIBN
|
$11.7M |
| 5 |
Vericel Corp
VCEL
|
$9.75M |
Sector Composition
| 1 | Healthcare | 96.82% |
| 2 | Consumer Staples | 2.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
Axsome Therapeutics
AXSM
$6.09B
| $1.79M | 0.2% |
24,900
+4,200
| +20% | +$302K |
|
77
Acadia Pharmaceuticals
ACAD
$4.34B
| $1.58M | 0.18% |
66,000
-124,000
| -65% | -$2.97M |
|
78
Aclaris Therapeutics
ACRS
$223M
| $1.57M | 0.17% |
151,000
-98,000
| -39% | -$1.02M |
|
|
CERE
79
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $1.46M | 0.16% |
46,000
-109,000
| -70% | -$3.47M |
|
80
Liquidia Corp
LQDA
$2.52B
| $1.37M | 0.15% |
+175,000
| New | +$1.37M |
|
81
Mineralys Therapeutics
MLYS
$1.94B
| $1.31M | 0.15% |
76,817
-196,424
| -72% | -$3.35M |
|
82
Avita Medical
RCEL
$116M
| $1.28M | 0.14% |
+75,000
| New | +$1.28M |
|
83
Protagonist Therapeutics
PTGX
$3.62B
| $1.1M | 0.12% |
+39,800
| New | +$1.1M |
|
84
Y-mAbs Therapeutics
YMAB
$390M
| $1.07M | 0.12% |
157,182
+70,000
| +80% | +$475K |
|
85
Immunocore
IMCR
$1.78B
| $983K | 0.11% |
+16,400
| New | +$983K |
|
|
ALPN
86
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $905K | 0.1% |
+88,073
| New | +$905K |
|
87
Viridian Therapeutics
VRDN
$1.59B
| $809K | 0.09% |
+34,000
| New | +$809K |
|
|
MORF
88
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $780K | 0.09% |
+13,600
| New | +$780K |
|
89
Immunic
IMUX
$79.4M
| $753K | 0.08% |
300,000
| – | – |
|
90
Ventyx Biosciences
VTYX
$184M
| $699K | 0.08% |
+21,300
| New | +$699K |
|
91
Rhythm Pharmaceuticals
RYTM
$6.75B
| $637K | 0.07% |
+38,600
| New | +$637K |
|
92
Pliant Therapeutics
PLRX
$105M
| $607K | 0.07% |
+33,500
| New | +$607K |
|
93
Xilio Therapeutics
XLO
$37.5M
| $595K | 0.07% |
226,941
| – | – |
|
94
Pulmonx
LUNG
$67.6M
| $538K | 0.06% |
41,000
-30,000
| -42% | -$393K |
|
95
Adverum Biotechnologies
ADVM
$68.2M
| $509K | 0.06% |
+32,000
| New | +$509K |
|
96
Celldex Therapeutics
CLDX
$1.57B
| $461K | 0.05% |
+13,600
| New | +$461K |
|
|
VRNA
97
Verona Pharma
VRNA
$9.18B
| $459K | 0.05% |
+21,700
| New | +$459K |
|
98
Indivior
INDV
$3.08B
| $443K | 0.05% |
+18,624
| New | +$443K |
|
99
Travere Therapeutics
TVTX
$1.75B
| $332K | 0.04% |
21,600
-213,000
| -91% | -$3.27M |
|
|
FNA
100
DELISTED
Paragon 28, Inc.
FNA
| $177K | 0.02% |
10,000
-194,018
| -95% | -$3.44M |
|